A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)
Phase of Trial: Phase III
Latest Information Update: 22 Apr 2018
At a glance
- Drugs Rituximab (Primary)
- Indications B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms JASMINE
- Sponsors Amgen
- 31 Aug 2017 Planned End Date changed from 13 Mar 2018 to 13 Dec 2018.
- 31 Aug 2017 Planned primary completion date changed from 13 Mar 2018 to 13 Dec 2018.
- 10 Jun 2017 Biomarkers information updated